DC-SIGN (CD209) Expression Is IL-4 Dependent and Is Negatively Regulated by IFN, TGF-β, and Anti-Inflammatory Agents
- 15 March 2002
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 168 (6) , 2634-2643
- https://doi.org/10.4049/jimmunol.168.6.2634
Abstract
Dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN) is a monocyte-derived dendritic cell (MDDC)-specific lectin which participates in dendritic cell (DC) migration and DC-T lymphocyte interactions at the initiation of immune responses and enhances trans-infection of T cells through its HIV gp120-binding ability. The generation of a DC-SIGN-specific mAb has allowed us to determine that the acquisition of DC-SIGN expression during the monocyte-DC differentiation pathway is primarily induced by IL-4, and that GM-CSF cooperates with IL-4 to generate a high level of DC-SIGN mRNA and cell surface expression on immature MDDC. IL-4 was capable of inducing DC-SIGN expression on monocytes without affecting the expression of other MDDC differentiation markers. By contrast, IFN-α, IFN-γ, and TGF-β were identified as negative regulators of DC-SIGN expression, as they prevented the IL-4-dependent induction of DC-SIGN mRNA on monocytes, and a similar inhibitory effect was exerted by dexamethasone, an inhibitor of the monocyte-MDDC differentiation pathway. The relevance of the inhibitory action of dexamethasone, IFN, and TGF-β on DC-SIGN expression was emphasized by their ability to inhibit the DC-SIGN-dependent HIV-1 binding to differentiating MDDC. These results demonstrate that DC-SIGN, considered as a MDDC differentiation marker, is a molecule specifically expressed on IL-4-treated monocytes, and whose expression is subjected to a tight regulation by numerous cytokines and growth factors. This feature might help in the development of strategies to modulate the DC-SIGN-dependent cell surface attachment of HIV for therapeutic purposes.Keywords
This publication has 42 references indexed in Scilit:
- The biology of Stat4 and Stat6Oncogene, 2000
- DC-SIGNCell, 2000
- Transforming Growth Factor β1, in the Presence of Granulocyte/Macrophage Colony-stimulating Factor and Interleukin 4, Induces Differentiation of Human Peripheral Blood Monocytes into Dendritic Langerhans CellsThe Journal of Experimental Medicine, 1998
- Origin, maturation and antigen presenting function of dendritic cellsCurrent Opinion in Immunology, 1997
- A Role for Endogenous Transforming Growth Factor β1 in Langerhans Cell Biology: The Skin of Transforming Growth Factor β1 Null Mice Is Devoid of Epidermal Langerhans CellsThe Journal of Experimental Medicine, 1996
- Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitorNature, 1996
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994
- Allergy‐associated Iϵ and Fcϵ receptor II (CD23b) genes activated via binding of an interleukin‐4‐induced transcription factor to a novel responsive elementEuropean Journal of Immunology, 1993
- Inhibition of human macrophage colony formation by interleukin 4.The Journal of Experimental Medicine, 1989
- Human recombinant interleukin 4 induces Fc epsilon receptors (CD23) on normal human B lymphocytes.The Journal of Experimental Medicine, 1987